A Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas
Metastatic Uveal Melanoma
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 66 (final count)
- Started
- Jul 4, 2022
- Main results expected
- Oct 1, 2027
- Fully finished
- Oct 1, 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Phase I (Dose Escalation): Incidence and severity of dose limiting toxicities (DLTs) during the first 28 days of treatment.
Measured over: 28 days
Phase I (Dose Escalation): Incidence and severity of adverse events (AEs) and serious adverse events (SAEs)
Measured over: 9 months
Phase I (Dose Escalation): Frequency of dose interruptions, reductions, and discontinuations
Measured over: 9 months
Phase II: Overall Response rate (ORR) per RECIST 1.1
Measured over: 17 months
Changes Tremor has spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT05415072 · record last updated 2026-07-28 · checked 2026-11-09 15:47 UTC